サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536115

動脈硬化治療薬の世界市場

Atherosclerosis Drugs

出版日
ページ情報
英文 389 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
動脈硬化治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 389 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

動脈硬化治療薬の世界市場は2030年までに253億米ドルに達する見込み

2023年に206億米ドルと推定される動脈硬化治療薬の世界市場は、2023～2030年の分析期間においてCAGR 3.0%で成長し、2030年には253億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗血小板薬・抗凝固薬は、CAGR 3.8%を記録し、分析期間終了時には132億米ドルに達すると予測されます。ACE阻害剤セグメントの成長率は、分析期間中CAGR 2.4%と推定されます。

米国市場は56億米ドルと推定、中国はCAGR 5.5%で成長予測

米国の動脈硬化治療薬市場は2023年に56億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに50億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは5.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.7%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の動脈硬化治療薬市場- 主要動向と促進要因のまとめ

アテローム性動脈硬化症は、動脈内のプラークの蓄積を特徴とする慢性疾患であり、血流を妨げたり血栓症を引き起こしたりする動脈壁の狭窄や硬化をもたらします。アテローム性動脈硬化症は、心臓発作や脳卒中などの心血管系疾患（CVD）の主な原因であり、世界の主要死因の一つです。アテローム性動脈硬化症の治療に使用される薬剤は、主に血中のコレステロールやトリグリセリドの高濃度といった症状の根本的な原因を減らし、高血圧などの危険因子を管理することを目的としています。スタチン系薬剤は、このカテゴリーで最も広く使用されている薬剤であり、コレステロール合成に関与する酵素を阻害することによって作用し、血中のコレステロール値を低下させる。その他の薬剤クラス別には、フィブラート系薬剤、ナイアシン、胆汁酸分泌抑制剤、そして低比重リポ蛋白（LDL）コレステロールを有意に低下させるPCSK9阻害剤などの新しい薬剤があり、遺伝的脂質異常症患者やスタチン系薬剤が十分に効かない患者に特に有用です。

アテローム性動脈硬化症の治療における最近の進歩は、単にコレステロール値を管理するだけでなく、心血管系のリスク軽減に対するより包括的なアプローチに焦点を当てています。これには、プラークの蓄積と不安定性の原因となる炎症プロセスを標的とする薬剤の開発が含まれます。例えば、カナキヌマブのような抗炎症治療は、アテローム性動脈硬化に関連する特定の炎症経路を標的とすることで、心血管イベントのリスクを低下させる可能性を示しています。さらに、精密医療を治療プロトコールに組み込むことで、個々の遺伝子プロファイルに基づいたオーダーメイドの治療戦略が可能になり、薬物療法の有効性と安全性が向上します。また、遺伝子編集技術やRNA療法の登場は、分子レベルで動脈硬化の要因を直接修正する可能性を秘め、従来の医薬品アプローチよりも永続的な解決策を提供する可能性があります。

動脈硬化治療薬市場の成長は、世界の心血管疾患の有病率の増加、一般住民の心臓の健康に対する意識の高まりと積極的な管理、薬剤研究開発の著しい進歩など、いくつかの要因によってもたらされます。世界の人口の高齢化と、食生活の乱れ、運動不足、喫煙などの生活習慣が、動脈硬化や関連する心血管系疾患の発症率上昇に寄与しており、効果的な治療に対する需要を煽っています。この分野における製薬業界の技術革新への取り組みは、薬剤耐性への対応や長期使用に伴う副作用の軽減に特に重点を置いた、より効果的で安全な治療法の開発のための研究開発への多額の投資によって証明されています。さらに、公衆衛生キャンペーンや支援政策を通じて心血管疾患の負担を軽減する政府の取り組みが、予防薬や治療薬の使用を促進しています。患者教育が改善し検診が普及するにつれて、危険因子を効果的に管理するための薬物療法の早期採用が増加し、市場の成長をさらに促進すると予想されます。

調査対象企業の例（注目の86社）

  • AdvaCare Pharma
  • Astrazeneca Pharmaceuticals LP
  • Cayman Chemical Company
  • Crescent Pharma Ltd
  • Kowa Co., Ltd.
  • Lupin Pharmaceuticals, Inc
  • MilliporeSigma
  • Novartis International AG
  • Pfizer, Inc.
  • Rosemont Pharmaceuticals Limited
  • Sterling Biotech Ltd
  • Teva Pharmaceuticals USA, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Viatris, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26638

Global Atherosclerosis Drugs Market to Reach US$25.3 Billion by 2030

The global market for Atherosclerosis Drugs estimated at US$20.6 Billion in the year 2023, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiplatelet & Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$13.2 Billion by the end of the analysis period. Growth in the ACE Inhibitors segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 5.5% CAGR

The Atherosclerosis Drugs market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.0 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Atherosclerosis Drugs Market - Key Trends and Drivers Summarized

Atherosclerosis is a chronic condition characterized by the accumulation of plaque within the arteries, leading to narrowed and stiffened artery walls which can impede blood flow or lead to thrombosis. Atherosclerosis is a principal cause of cardiovascular diseases (CVDs), such as heart attacks and strokes, which are among the leading causes of death worldwide. Drugs used to treat atherosclerosis are primarily aimed at reducing the underlying causes of the condition, such as high levels of cholesterol and triglycerides in the blood, and managing risk factors like high blood pressure. Statins are the most widely used class of drugs in this category and work by inhibiting the enzyme involved in cholesterol synthesis, thereby lowering cholesterol levels in the blood. Other drug classes include fibrates, niacin, bile acid sequestrants, and newer agents like PCSK9 inhibitors, which significantly reduce low-density lipoprotein (LDL) cholesterol and are particularly useful in patients with genetic lipid disorders or those who do not respond adequately to statins.

Recent advancements in the treatment of atherosclerosis focus on a more comprehensive approach to cardiovascular risk reduction, beyond merely managing cholesterol levels. This includes the development of drugs that target inflammatory processes which contribute to plaque build-up and instability. For instance, anti-inflammatory treatments such as canakinumab have shown potential in reducing the risk of cardiovascular events by targeting specific inflammatory pathways associated with atherosclerosis. Additionally, the integration of precision medicine into treatment protocols allows for tailored therapeutic strategies based on individual genetic profiles, improving the efficacy and safety of drug therapies. The advent of gene editing technologies and RNA therapies also holds promise in directly modifying the contributors to atherosclerosis at the molecular level, potentially offering more permanent solutions than traditional pharmaceutical approaches.

The growth in the atherosclerosis drugs market is driven by several factors, including the increasing prevalence of cardiovascular diseases globally, heightened awareness and proactive management of heart health among the general population, and significant advancements in drug research and development. An aging global population and lifestyle factors such as poor diet, lack of physical activity, and smoking contribute to the rising incidence of atherosclerosis and related cardiovascular conditions, fueling demand for effective treatments. The pharmaceutical industry's commitment to innovation in this area is evidenced by substantial investments in R&D for developing more effective and safer therapies, with a particular emphasis on addressing drug resistance and reducing side effects associated with long-term use. Furthermore, government initiatives to reduce the burden of cardiovascular diseases through public health campaigns and supportive policies promote the use of preventive and therapeutic drugs. As patient education improves and screening becomes more widespread, the early adoption of drug therapies to manage risk factors effectively is expected to rise, further propelling market growth.

Select Competitors (Total 86 Featured) -

  • AdvaCare Pharma
  • Astrazeneca Pharmaceuticals LP
  • Cayman Chemical Company
  • Crescent Pharma Ltd
  • Kowa Co., Ltd.
  • Lupin Pharmaceuticals, Inc
  • MilliporeSigma
  • Novartis International AG
  • Pfizer, Inc.
  • Rosemont Pharmaceuticals Limited
  • Sterling Biotech Ltd
  • Teva Pharmaceuticals USA, Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Viatris, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Atherosclerosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Drives Market Growth
    • Advances in Lipid-Lowering Therapies Propel Market Demand
    • Increasing Focus on Preventive Cardiology Strengthens Business Case for Atherosclerosis Drugs
    • Expansion of Hypertension and Diabetes Management Spurs Market Adoption
    • Growing Awareness of Atherosclerosis and Its Risk Factors Expands Addressable Market Opportunity
    • Rising Demand for Statins and PCSK9 Inhibitors Drives Market Dynamics
    • Expansion of Health Insurance Coverage Strengthens Market Adoption
    • Increasing Availability of Combination Drugs Strengthens Market Dynamics
    • Rising Demand for Biomarker-Based Therapies Expands Market Reach
    • Growth of the Aging Population Sets the Stage for Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Atherosclerosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Atherosclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Atherosclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiplatelet & Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiplatelet & Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiplatelet & Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cholesterol Lowering Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cholesterol Lowering Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cholesterol Lowering Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Atherosclerosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Atherosclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Atherosclerosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • INDIA
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Atherosclerosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Atherosclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Atherosclerosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Atherosclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AFRICA
    • Atherosclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Atherosclerosis Drugs by Drug Type - Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Atherosclerosis Drugs by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet & Anticoagulants, ACE Inhibitors, Cholesterol Lowering Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Atherosclerosis Drugs by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Atherosclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Atherosclerosis Drugs by Distribution Channel - Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Atherosclerosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION